Increased fibulin-1 plasma levels in polycystic ovary syndrome (PCOS) patients: possible contribution to the link between PCOS and cardiovascular risk

被引:7
|
作者
Scarinci, E. [1 ]
Tropea, A. [1 ]
Russo, G. [2 ]
Notaristefano, G. [1 ]
Messana, C. [1 ]
Alesiani, O. [1 ]
Fabozzi, S. M. [1 ]
Lanzone, A. [1 ]
Apa, R. [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Dept Obstet & Gynecol, Lgo Agostino Gemelli 8, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dept Cardiovasc Sci, Rome, Italy
关键词
PCOS; Fibulin-1; Cardiovascular risk; Hormonal assay; TYPE-2; DIABETES-MELLITUS; FLOW-MEDIATED DILATION; NORMAL-WEIGHT WOMEN; INSULIN-RESISTANCE; ENDOTHELIAL FUNCTION; GLUCOSE-TOLERANCE; VASCULAR FUNCTION; ASSOCIATION; PREVALENCE; METFORMIN;
D O I
10.1007/s40618-018-0891-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PurposeTo investigate a possible relation between fibulin-1 plasma levels and PCOS.DesignELISA quantitative determination of human fibulin-1.Methods50 women with PCOS and 40 control patients who attended the Unit of Human Reproductive Pathophysiology, Universita Cattolica del Sacro Cuore, Rome, were enrolled. Ultrasonographic pelvic examinations, hormonal profile assays, oral tolerance test OGTT, lipid profile and ELISA quantitative determination of human fibulin-1 were performed.ResultsFibulin-1 levels were found to be statistically significantly higher in PCOS patients than in matched control women. No statistically significant positive correlation was found between fibulin-1 and AUCi, HOMA-IR, total cholesterol, LDL, AMH, androstenedione and FAI, whereas a statistically significant positive correlation was found between fibulin-1 and 17OHP (p=0.016) in the PCOS group. However, multivariable linear regression analysis showed that 17 OH P did not independently predict fibulin-1 levels (p=0.089).ConclusionsOur data could contribute to explain the hypothesized increased cardiovascular risk and vascular damage in patients with PCOS. A better understanding of the cellular and molecular mechanisms involved in cardiometabolic disorders associated with PCOS is mandatory to identify new therapeutic strategies to eventually prevent the progression of cardiovascular diseases in these patients.
引用
收藏
页码:91 / 96
页数:6
相关论文
共 50 条
  • [1] Increased fibulin-1 plasma levels in polycystic ovary syndrome (PCOS) patients: possible contribution to the link between PCOS and cardiovascular risk
    E. Scarinci
    A. Tropea
    G. Russo
    G. Notaristefano
    C. Messana
    O. Alesiani
    S. M. Fabozzi
    A. Lanzone
    R. Apa
    [J]. Journal of Endocrinological Investigation, 2019, 42 : 91 - 96
  • [2] Increased Fibulin-1 Plasma Levels in Polycystic Ovary Syndrome (PCOS) Patients: A Possible Contribution To the Link Between PCOS and Cardiovascular Risk.
    Scarinci, Elisa
    Tropea, Anna
    Moro, Francesca
    Romani, Federica
    Alesiani, Ornella
    Lanzone, Antonio
    Apa, Rosanna
    [J]. REPRODUCTIVE SCIENCES, 2015, 22 : 313A - 313A
  • [3] The polycystic ovary syndrome (pcos) status and cardiovascular risk in young women
    Ilie, Ioana R.
    Pepene, Carmen E.
    Marian, Ioan
    Mocan, Teodora
    Hazi, Georgeta
    Dragotoiu, Gheorghe
    Ilie, Razvan
    Mocan, Lucian
    Duncea, Ileana
    [J]. CENTRAL EUROPEAN JOURNAL OF MEDICINE, 2011, 6 (01): : 64 - 75
  • [4] Possible Effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): An Update
    Profili, Nicia I.
    Castelli, Roberto
    Gidaro, Antonio
    Manetti, Roberto
    Maioli, Margherita
    Petrillo, Marco
    Capobianco, Giampiero
    Delitala, Alessandro P.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [5] Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women without PCOS
    Hillman, Jennifer K.
    Johnson, Lauren N. C.
    Limaye, Meghana
    Feldman, Rebecca A.
    Sammel, Mary
    Dokras, Anuja
    [J]. FERTILITY AND STERILITY, 2014, 101 (02) : 530 - 535
  • [6] Increased masked hypertension prevalence in patients with polycystic ovary syndrome (PCOS)
    Ozkan, Selcuk
    Yilmaz, Omer Caglar
    Yavuz, Bunyamin
    [J]. CLINICAL AND EXPERIMENTAL HYPERTENSION, 2020, 42 (08) : 681 - 684
  • [7] DO WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) HAVE AN INCREASED RISK OF MISCARRIAGE?
    Alvarez, J.
    Wu, A.
    Stephenson, M.
    Scoccia, B.
    [J]. FERTILITY AND STERILITY, 2010, 94 (04) : S198 - S199
  • [8] Decreased Neuropeptide Action Associated with Cardiovascular Risk in Migraine Patients with Polycystic Ovary Syndrome (PCOS)
    Al-Hassany, L.
    Zick, B. K. T.
    Linstra, K. M.
    Meun, C.
    Van der Ham, K.
    Van den Berg, J.
    Boersma, E. H.
    Danser, A. H. J.
    Fauser, B. C. J.
    Laven, J. S.
    Wermer, M. J. H.
    Terwindt, G. M.
    van den Brink, A. Maassen
    [J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 204 - 204
  • [9] Decreased Neuropeptide Action Associated with Cardiovascular Risk in Migraine Patients with Polycystic Ovary Syndrome (PCOS)
    Al-Hassany, L.
    Zick, B. K. T.
    Linstra, K. M.
    Meun, C.
    Van der Ham, K.
    Van den Berg, J.
    Boersma, E. H.
    Danser, A. H. J.
    Fauser, B. C. J.
    Laven, J. S.
    Wermer, M. J. H.
    Terwindt, G. M.
    Van den Brink, A. Maassen
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 136 - 137
  • [10] Inflammation and polycystic ovary syndrome (PCOS). Utilising proteomic analysis to unravel the link between inflammatory proteins and PCOS in adolescents
    Gunn, Harriet
    Oberg, Emma
    Hallqvist, Jenny
    Hirschberg, Angelica Linden
    Steinbeck, Katharine
    Mills, Kevin
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 2): : 384 - 384